LDS/Medical Tests/Microsomal epoxide hydrolase 1 (EPHX1) Gene Variation

Microsomal epoxide hydrolase 1 (EPHX1) Gene Variation

Microsomal epoxide hydrolase 1 (EPHX1) is an important biological transformation enzyme (EC 3.3.2.9) responsible for the conversion of epoxides to diols. The enzyme is coded by the EPHX1 gene located 1q 42.12. In the human body, epoxides are released from the degradation of aromatic compounds which are conjugated and detoxified by EPHX1 into trans-dihydrodiols which can be easily excreted. The enzyme is localized in the endoplasmic reticulum of almost all body tissues and plays an important role in detoxifying xenobiotics. Simultaneously, it is expressed in the sinusoidal side of the membrane and is responsible for the sodium-dependent transport of bile acids from plasma into hepatocytes. The N-terminal of the enzyme anchors the enzyme to the membranes while the C-terminal is the catalytic center.

EPHX1 functions as an anti-carcinogenic factor since it detoxifies carcinogenic drugs containing benzene, butadiene, and styrene. Hyperactivity of EPHX1 may conversely lead to carcinogenesis via the activation of pro-carcinogens like aromatic hydrocarbons. Different single-nucleotide polymorphisms (SNPs) and variants have been discovered in the gene that results in either compromised function or overactivity of the enzyme. Abnormal enzyme leads to the diminished entry of serum bile acids into the hepatocytes causing hypercholanemia. Hypercholanemia is characterized by higher levels of serum bile acids, and fat malabsorption. However, this can also be caused by mutations in TJP2 and BAAT genes and these should be investigated if a negative rest result is obtained from EPHX1 examination.

Studies have also found an association between EPHX1 mutations and preeclampsia. Preeclampsia is characterized by hypertension in pregnant women with proteinuria by the 20th week of pregnancy. This both increases the risk of miscarriage and premature birth but it is also one of the top 4 causes of maternal mortality. Patients with EPHX1 mutations may also be at risk for cancers of the lung, prostate, cervix, colorectum, or bladder. Apart from these, EPHX1 is differentially and abundantly expressed in the normal liver while it is decreased in hepatic metastasis. Therefore, the demonstration of the decreased enzyme through immunohistochemistry might serve a biomarker role in diagnosing pre-neoplastic liver abnormalities.

  • As an aid in the diagnosis of hypercholanemia
  • Used as a part of the Pharmacogenetics for Anticonvulsants drugs (Carbamazepine, Phenytoin)

A positive result indicates the presence of mutations or polymorphisms in the EPHX1 gene.

A negative result indicates the absence of mutations of polymorphisms in the EPHX1 gene.

Negative for mutations analysis (no mutations or pathogenic variants detected)

Real-time Polymerase chain reaction (PCR)-target variant analysis, deletion/duplication analysis, sequence analysis of the entire coding region.

Whole blood, Lavender-top (EDTA) tube.

Acceptable specimens: extracted DNA, saliva/buccal swabs. 

Stability whole blood

  • Ambient: 3-5 days
  • Refrigerated: 1 week (preferred)
  • Frozen: 1 month
Serum bile acids, bilirubin, liver function tests, stool fat analysis, amylase, lipase, TJP2, and BAAT gene mutation analysis.
3-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login